Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report
Journal of Thoracic Oncology(2024)
摘要
Adjuvant osimertinib represents a recent paradigm shift in the management of resected EGFR-mutated lung cancer. The optimal subsequent treatment of patients who relapse after completion of 3 years of adjuvant osimertinib is unknown. Here, we report two cases of complete response to osimertinib rechallenge after relapse from previous adjuvant osimertinib use, and a serial molecular panel exhibiting a lack of acquired resistance mechanisms. Future prospective studies are warranted to confirm the optimal treatment of patients who relapse after previous adjuvant osimertinib.
更多查看译文
关键词
NSCLC,Adjuvant,Osimertinib,Resistance,Case report
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要